Linked Life Data

16183547

Source:http://linkedlifedata.com/resource/pubmed/id/16183547

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
2005-9-26
pubmed:abstractText
Aberrant angiogenesis is essential for the progression of solid tumors and hematological malignancies. Antiangiogenic therapy is one of the most promising approaches to treat such diseases. Dobesilate is an oral agent for treatment of vascular complications of diabetic retinopathy. We have examined the possibility that this compound could interfere with the process of angiogenesis in a mouse gelatine sponge assay using acidic fibroblast growth factor (aFGF) as an inducer of neovascularization. According to the results reported here, dobesilate remarkably reduced vessel ingrowth in aFGF-containing subcutaneous sponges in mice. These findings suggest that dobesilate could be an effective agent in the treatment of angiogenesis-dependent diseases involving FGFs.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0949-2321
pubmed:author
pubmed:issnType
Print
pubmed:day
12
pubmed:volume
10
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
369-72
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
Dobesilate is an angiogenesis inhibitor.
pubmed:affiliation
Servicio de Histologia, Departamento de Investigacion, Hospital Ramon y Cajal, Ctra. de Colmenar, km. 9.100, E-28034-Madrid, Spain. pedro.cuevas@hrc.es
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't